Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
J Frontier Co., Ltd. (2934.T)
Tokyo, JP
J Frontier Co.,Ltd. engages in the healthcare sales, medical care sales, and healthcare marketing businesses in Japan. The company operates SOKUYAKU, a platform for online medical treatment, online medication guidance, home delivery of prescription drugs, and digital transformation support for medical institutions. The company also sells health foods, health, beauty, education, healing, medicine, and medical care products through mail order; and provides product sales promotion support services. In addition, it offers Internet advertising for medical institutions and healthcare-related companies; and web marketing, in-store and TV shopping distribution, BPO support for logistics, etc. J Frontier Co.,Ltd. was incorporated in 2008 and is based in Shibuya, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.69% | -2.53% | -4.09% | +21.87% | +2.93% | +22.70% | +0.56% | -31.26% | -51.33% | -51.33% | -51.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+21.4% ★ Q1'26: +3.6% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+104.0% ★ Q1'26: +129.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+3.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+1.4% Q1'26: +7.8% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+4.4% Q1'26: +20.8% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+3.9% Q1'26: +6.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×4.75× Q1'26: 2.26× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
May 2022 actual |
May 2023 actual |
May 2024 actual |
May 2025 actual |
May 2026 1 Rev. Ana. 1 EPS Ana. |
May 2027 1 Rev. Ana. 1 EPS Ana. |
May 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
11.88B
est: 10.50B (+13.1%)
|
16.84B
est: 16.67B (+1.1%)
|
17.71B
est: 25.00B (-29.1%)
|
21.50B
est: 30.00B (-28.3%)
|
46.93B
46.93B – 46.93B
+56.4% YoY
|
68.77B
68.77B – 68.77B
+46.5% YoY
|
100.00B
100.00B – 100.00B
+45.4% YoY
|
| EBITDA |
760.67M
est: 61.64M (+1,134.0%)
|
-1.54B
est: 97.88M (-1,672.2%)
|
-1.22B
est: 146.81M (-932.5%)
|
914.54M
est: 176.17M (+419.1%)
|
275.57M
275.57M – 275.57M
+56.4% YoY
|
403.84M
403.84M – 403.84M
+46.5% YoY
|
587.22M
587.22M – 587.22M
+45.4% YoY
|
| EBIT |
701.88M
est: -99.84M (+803.0%)
|
-1.84B
est: -158.54M (-1,057.9%)
|
-1.63B
est: -237.77M (-587.0%)
|
307.78M
est: -285.33M (+207.9%)
|
-446.33M
-446.33M – -446.33M
-56.4% YoY
|
-654.08M
-654.08M – -654.08M
-46.5% YoY
|
-951.09M
-951.09M – -951.09M
-45.4% YoY
|
| Net Income |
400.52M
est: 603.98M (-33.7%)
|
-1.90B
est: -2.45B (+22.3%)
|
-2.09B
est: 383.76M (-643.7%)
|
87.57M
est: 1.63B (-94.6%)
|
4.14B
4.14B – 4.14B
+153.7% YoY
|
9.73B
9.73B – 9.73B
+134.8% YoY
|
17.82B
17.82B – 17.82B
+83.1% YoY
|
| SGA |
4.61B
est: 4.33B (+6.4%)
|
8.63B
est: 6.88B (+25.5%)
|
8.51B
est: 10.32B (-17.6%)
|
—
est: 12.38B (-100.0%)
|
19.37B
19.37B – 19.37B
+56.4% YoY
|
28.38B
28.38B – 28.38B
+46.5% YoY
|
41.27B
41.27B – 41.27B
+45.4% YoY
|
| EPS |
90.64
est: 118.70 (-23.6%)
|
-410.60
est: -480.59 (+14.6%)
|
-426.06
est: 75.42 (-664.9%)
|
17.42
est: 321.02 (-94.6%)
|
814.38
814.38 – 814.38
+153.7% YoY
|
1,912.30
1,912.30 – 1,912.30
+134.8% YoY
|
3,502.02
3,502.02 – 3,502.02
+83.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Atsuhiro Nakamura | President, Chief Executive Officer & Representative Director | — | male |
| Katsutoshi Minagawa | Executive Officer of Corporate Planning Department | — | — |
| Nana Fukazawa | Executive Officer & GM of Sokuyaku Business Division | — | male |
| Yuya Higuchi | Chairman of the Board, Exe. Officer, Chief Financial Officer and Head of Corporation Planning Headquarters & Corp. Division | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2934.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
